Cevira in Cervical HSIL: Asieris Announces Presentation of Data at the 2024 IPVC Conference Highlighting the Clearance Rate for Different HPV Types
Press Release – Oslo, Norway, November 12, 2024 – Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has communicated today regarding a new poster presentation of Cevira clinical trial data at the 2024 International Papillomavirus Conference (IPVC).
Study data from the international multicenter phase III clinical study of Cevira® (APL-1702), its non-surgical treatment product candidate for cervical High-Grade Squamous Intraepithelial Lesion (HSIL), has been published by the IPVC this week, as a poster, focusing on the analysis of data on the clearance rate for different HPV types and different follow-up times.
Read Asieris’ full media release here.
About Cevira® (APL-1702) and Asieris
Based on the principles of photodynamic therapy, Cevira® (APL-1702) is undergoing clinical development for use as a photosensitizer in combination with light activation for the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL) in patients aged 18 years and above, excluding carcinoma in situ. Photocure developed Cevira through Phase I and Phase II clinical trials, and in July 2019, Asieris Meditech Co., Ltd licensed from Photocure the worldwide rights to develop and commercialize this drug-device combination product candidate. In November 2020, Asieris initiated a Phase III clinical trial for APL-1702 (Cevira) which achieved its primary endpoint in September 2023 (Clinical trial number: NCT04484415). The new drug application for Cevira was accepted by the National Medical Products Administration (NMPA) in May 2024, and is now undergoing regulatory review in China.
Asieris Pharmaceuticals(688176.SH) is a global biopharmaceutical company specializing in the discovery, development, and commercialization of innovative drugs for genitourinary tumors and related diseases.
Questions about the clinical development, regulatory application, or commercial strategy for APL-1702 (Cevira) should be directed to Asieris. Investors - Asieris Pharmaceuticals
About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com, www.hexvix.com, www.cysview.com
Note to editors:
All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA.
This press release may contain product details and information which are not valid, or a product is not accessible, in your country. Please be aware that Photocure does not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.